GB201720351D0 - Selecting for developability in drug discovery - Google Patents

Selecting for developability in drug discovery

Info

Publication number
GB201720351D0
GB201720351D0 GBGB1720351.4A GB201720351A GB201720351D0 GB 201720351 D0 GB201720351 D0 GB 201720351D0 GB 201720351 A GB201720351 A GB 201720351A GB 201720351 D0 GB201720351 D0 GB 201720351D0
Authority
GB
United Kingdom
Prior art keywords
developability
selecting
drug discovery
discovery
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1720351.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iontas Ltd
Original Assignee
Iontas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iontas Ltd filed Critical Iontas Ltd
Priority to GBGB1720351.4A priority Critical patent/GB201720351D0/en
Publication of GB201720351D0 publication Critical patent/GB201720351D0/en
Priority to AU2018379426A priority patent/AU2018379426B2/en
Priority to US16/767,727 priority patent/US11499150B2/en
Priority to PCT/EP2018/083698 priority patent/WO2019110691A1/en
Priority to CN201880079095.7A priority patent/CN111448314B/zh
Priority to JP2020530462A priority patent/JP7744746B2/ja
Priority to CA3083571A priority patent/CA3083571A1/en
Priority to EP18826197.8A priority patent/EP3720959A1/en
Priority to JP2023174103A priority patent/JP2024009895A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB1720351.4A 2017-12-06 2017-12-06 Selecting for developability in drug discovery Ceased GB201720351D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1720351.4A GB201720351D0 (en) 2017-12-06 2017-12-06 Selecting for developability in drug discovery
AU2018379426A AU2018379426B2 (en) 2017-12-06 2018-12-05 Selecting for developability of polypeptide drugs in eukaryotic cell display systems
US16/767,727 US11499150B2 (en) 2017-12-06 2018-12-05 Selecting for developability of polypeptide drugs in eukaryotic cell display systems
PCT/EP2018/083698 WO2019110691A1 (en) 2017-12-06 2018-12-05 Selecting for developability of polypeptide drugs in eukaryotic cell display systems
CN201880079095.7A CN111448314B (zh) 2017-12-06 2018-12-05 根据可开发性选择真核细胞展示系统中的多肽药物
JP2020530462A JP7744746B2 (ja) 2017-12-06 2018-12-05 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択
CA3083571A CA3083571A1 (en) 2017-12-06 2018-12-05 Selecting for developability of polypeptide drugs in eukaryotic cell display systems
EP18826197.8A EP3720959A1 (en) 2017-12-06 2018-12-05 Selecting for developability of polypeptide drugs in eukaryotic cell display systems
JP2023174103A JP2024009895A (ja) 2017-12-06 2023-10-06 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720351.4A GB201720351D0 (en) 2017-12-06 2017-12-06 Selecting for developability in drug discovery

Publications (1)

Publication Number Publication Date
GB201720351D0 true GB201720351D0 (en) 2018-01-17

Family

ID=60950392

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1720351.4A Ceased GB201720351D0 (en) 2017-12-06 2017-12-06 Selecting for developability in drug discovery

Country Status (8)

Country Link
US (1) US11499150B2 (enExample)
EP (1) EP3720959A1 (enExample)
JP (2) JP7744746B2 (enExample)
CN (1) CN111448314B (enExample)
AU (1) AU2018379426B2 (enExample)
CA (1) CA3083571A1 (enExample)
GB (1) GB201720351D0 (enExample)
WO (1) WO2019110691A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3786292A1 (en) * 2016-01-08 2021-03-03 Maxion Therapeutics Limited Binding members with altered diversity scaffold domains
GB201720162D0 (en) * 2017-12-04 2018-01-17 Univ Oxford Innovation Ltd Method
WO2021018114A1 (zh) * 2019-07-30 2021-02-04 中山康方生物医药有限公司 抗人p40蛋白域抗体及其用途
GB202014851D0 (en) 2020-09-21 2020-11-04 Iontas Ltd SARS-COV-2 antibodies
CN118525099A (zh) 2021-08-25 2024-08-20 艾恩塔斯有限公司 真核细胞中表达的蛋白质变体文库的制备
WO2023039528A1 (en) * 2021-09-10 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nanobody-mediated control of gene expression and epigenetic memory
US12091694B2 (en) 2022-11-18 2024-09-17 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
EP4646476A1 (en) 2023-01-06 2025-11-12 Seismic Therapeutic, Inc. Protease variants and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485943B2 (en) * 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
JP2010213725A (ja) * 1998-01-20 2010-09-30 Univ Illinois タンパク質の酵母細胞表面ディスプレイおよびその使用
US20050048578A1 (en) * 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
PT2702160T (pt) 2011-04-27 2020-07-30 Amyris Inc Métodos para modificação genómica
EP2794662A1 (en) 2011-12-22 2014-10-29 F.Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules

Also Published As

Publication number Publication date
US20210163923A1 (en) 2021-06-03
AU2018379426A1 (en) 2020-06-18
US11499150B2 (en) 2022-11-15
CN111448314A (zh) 2020-07-24
EP3720959A1 (en) 2020-10-14
JP7744746B2 (ja) 2025-09-26
WO2019110691A1 (en) 2019-06-13
CA3083571A1 (en) 2019-06-13
JP2021509010A (ja) 2021-03-18
JP2024009895A (ja) 2024-01-23
CN111448314B (zh) 2024-10-18
AU2018379426B2 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
GB201720351D0 (en) Selecting for developability in drug discovery
GB201622163D0 (en) Related entity discovery
ZA202004675B (en) Pharmaceutical combinations comprising an anti-ly75 antibody
EP3638658C0 (en) PHARMACEUTICAL COMPOUNDS
EP3006999A4 (en) Easy-to-carry self photography support
IL254818A0 (en) Ribociclib tablet
ZA201900019B (en) Pharmaceutical combinations
GB201704714D0 (en) Pharmaceutical compounds
GB201704965D0 (en) Pharmaceutical compounds
GB201703881D0 (en) Pharmaceutical compounds
ZAA201800549S (en) Tablets
SG11201800591TA (en) Tablet
GB201706806D0 (en) Pharmaceutical compounds
PT3728220T (pt) Compostos farmacêuticos
GB201704966D0 (en) Pharmaceutical compounds
EP3431079C0 (en) COMPRESSED
IL265252A (en) Stable pharmaceutical foam
PH32017000907S1 (en) Pharmaceutical tablets
AP00975S1 (en) Pharmaceutical tablets
AP00977S1 (en) Pharmaceutical tablets
AP00976S1 (en) Pharmaceutical tablets
GB201717005D0 (en) Pharmaceutical compounds
GB201600998D0 (en) Fastened tablet stand
GB201702051D0 (en) New Pharmaceutical use
GB201700867D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)